Cardiovascular diseases (CVD) remain the leading cause of death worldwide, and
pharmacotherapy of most of them is suboptimal. Thus, there is a clear unmet clinical need to …

Anticoagulants are the mainstay for the prevention and treatment of thrombosis. However,
bleeding complications remain a primary concern. Recent advances in understanding the …

Introduction: Bleeding risk is the dose-limiting concern with available anticoagulant/
antithrombotic therapies. Inhibition of Factor XIa decreases thrombin generation in the …

Sažetak In the year 2021, the universal definition and classification of heart failure (HF) was
published that defines HF as a clinical syndrome with symptoms and/or signs caused by a …

Heart failure (HF) prevalence remains high worldwide with significant sex-related and
regional differences in its presentation, management, and outcomes. In 2020, advances in …

Limitations of vitamin K antagonists as chronic oral anticoagulant therapy have largely been
supplanted by direct factor IIa and factor Xa inhibitor oral anticoagulants with similar efficacy …

The article provides a summary of the 2021 European Society of Cardiology (ESC)
Guidelines for the diagnosis and treatment of acute and chronic heart failure (CHF). The …

Background Heart disease is the# 1 killer worldwide, greater than all cancers combined.
This is despite the fact that, in the developed world, there has been a substantial decline in …

1134 Circulation Research October 27, 2017 pathway via factor (F) XII and thereby enhance
thrombin generation. Activated platelets release medium chain polyphosphate, which …

Heart failure with reduced ejection fraction (HFrEF) requires a multimodal treatment with
combination of several drugs as the cornerstone for symptomatic and prognostic …